Foundation date



#Biotechnology / R&D Services


Therapeutic areas

ANT01, a Phase IIa proprietary small molecule in the Prevention of Alzheimer Disease in well defined patients, is oriented to prevent in the US only at least 100.000 new AD cases per year by treatment of 1M patients life time. After 5 years of planned launch in 2030 and with a peak sales of 10B, this will save US healthcare costs by at least 50B giving ANT01 a very attractive value proposition.

Upcoming events

Latest news

  • ANeuroTech receives positive feedback from the FDA for its pivotal Phase IIIb development programme for ANT-01 as an adjunctive anti-depression drug for Major Depressive Disorder

    19 hours ago

  • Confo Therapeutics awarded EUR 1.7M VLAIO grant to expand application of ConfoBody┬« drug discovery and development technology in rare diseases

    Tuesday June 28th 2022

  • MRM Health starts clinical trial with next-generation optimized consortium therapeutic MH002 in Pouchitis

    Tuesday June 28th 2022